Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	75.75	78.64	105.76	181.56	114.63	207.14
Cash & Cash Equivalents	75.75	78.64	105.76	181.56	114.63	207.14
Cash Growth	-18.22%	-25.65%	-41.75%	58.39%	-44.66%	40.08%
Receivables	20.59	22.45	12.53	7.71	0	0
Inventory	8.45	5.07	6.7	5.51	0	0
Other Current Assets	3.48	4.96	5.45	7.47	7.73	4.82
Total Current Assets	108.27	111.11	130.45	202.26	122.36	211.96
Property, Plant & Equipment	1.33	1.64	2.34	5.69	6.39	4.04
Goodwill and Intangibles	2.54	2.63	2.99	1.66	0	0
Other Long-Term Assets	11.17	12.49	5.68	3.17	3.29	0.37
Total Long-Term Assets	15.05	16.76	11.01	10.52	9.68	4.41
Total Assets	123.32	127.87	141.46	212.78	132.05	216.37
Accounts Payable	6.73	6.06	14.18	13.55	9.37	8.52
Current Debt	0.89	0.9	0.87	1.78	1.97	0.52
Other Current Liabilities	9.99	13.17	13.24	12.54	8.2	4.55
Total Current Liabilities	17.61	20.13	28.28	27.88	19.54	13.59
Long-Term Debt	0.29	0.52	0.9	1.85	2.01	1.71
Other Long-Term Liabilities	6.23	6.24	3.05	2.95	4.66	2.16
Total Long-Term Liabilities	6.52	6.76	3.95	4.8	6.68	3.88
Total Liabilities	24.13	26.88	32.24	32.68	26.21	17.46
Total Debt	1.18	1.42	1.77	3.63	3.98	2.23
Debt Growth	-20.42%	-19.69%	-51.38%	-8.67%	78.43%	-
Retained Earnings	-464.1	-457.47	-436.04	-340.48	-285.2	-165.86
Comprehensive Income	0.85	0.45	1.33	1.37	-0.53	0.05
Shareholders' Equity	99.19	100.99	109.22	180.11	105.84	198.9
Net Cash / Debt	74.57	77.22	104	177.93	110.66	204.91
Net Cash / Debt Growth	-18.19%	-25.75%	-41.55%	60.80%	-46.00%	38.57%
Net Cash Per Share	1.70	1.77	2.38	4.12	2.76	5.82
Working Capital	90.66	90.98	102.16	174.39	102.83	198.37
Book Value Per Share	2.27	2.31	2.50	4.17	2.64	5.65

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).